Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma

1

CAR-T therapy is a standard treatment for refractory B-cell non-Hodgkin lymphomas, utilizing genetically engineered T-lymphocytes targeting CD19.
2

Lymphodepletion with fludarabine and cyclophosphamide is crucial for enhancing CAR-T cell engraftment, expansion, and persistence.
3

Less than half of patients achieve durable responses to CAR-T therapy, influenced by factors like tumor volume and CAR-T construction.
4

Clinical trials show that lymphodepletion improves overall response rates and survival in patients receiving CAR-T therapy for DLBCL.
5

Lymphodepletion alters the immune microenvironment, enhancing T-cell functionality by removing regulatory cells and increasing homeostatic cytokines.

Bone Marrow Transplantation

by Marta Canelo-Vilaseca, Mohamad Sabbah, Roberta Di Blasi, Caterina Cristinelli, Anna Sureda, Sophie Caillat-Zucman, Catherine Thieblemont
March 27, 2025

1